Defining progression in nonmuscle invasive bladder cancer: It is time for a new, standard definition

Donald Lamm, Raj Persad, Maurizio Brausi, Roger Buckley, J. Alfred Witjes, Joan Palou, Andreas Böhle, Ashish M. Kamat, Marc Colombel, Mark Soloway

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Purpose: Despite being one of the most important clinical outcomes in nonmuscle invasive bladder cancer, there is currently no standard definition of disease progression. Major clinical trials and meta-analyses have used varying definitions or have failed to define this end point altogether. A standard definition of nonmuscle invasive bladder cancer progression as determined by reproducible and reliable procedures is needed. We examine current definitions of nonmuscle invasive bladder cancer progression, and propose a new definition that will be more clinically useful in determining patient prognosis and comparing treatment options. Materials and Methods: The IBCG (International Bladder Cancer Group) analyzed published clinical trials and meta-analyses that examined nonmuscle invasive bladder cancer progression as of December 2012. The limitations of the definitions of progression used in these trials were considered, as were additional parameters associated with the advancement of nonmuscle invasive bladder cancer. Results: The most commonly used definition of nonmuscle invasive bladder cancer progression is an increase in stage from nonmuscle invasive to muscle invasive disease. Although this definition is clinically important, it fails to include other important parameters of advancing disease such as progression to lamina propria invasion and increase in grade. Conclusions: The IBCG proposes the definition of nonmuscle invasive bladder cancer progression as an increase in T stage from CIS or Ta to T1 (lamina propria invasion), development of T2 or greater or lymph node (N+) disease or distant metastasis (M1), or an increase in grade from low to high. Investigators should consider the use of this new definition to help standardize protocols and improve the reporting of progression.

Original languageEnglish
Pages (from-to)20-27
Number of pages8
JournalJournal of Urology
Volume191
Issue number1
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Meta-Analysis
Mucous Membrane
Clinical Trials
Disease Progression
Lymph Nodes
Research Personnel
Neoplasm Metastasis
Muscles

Keywords

  • administration
  • BCG vaccine
  • disease progression
  • drug therapy
  • intravesical
  • urinary bladder neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Lamm, D., Persad, R., Brausi, M., Buckley, R., Witjes, J. A., Palou, J., ... Soloway, M. (2014). Defining progression in nonmuscle invasive bladder cancer: It is time for a new, standard definition. Journal of Urology, 191(1), 20-27. https://doi.org/10.1016/j.juro.2013.07.102

Defining progression in nonmuscle invasive bladder cancer : It is time for a new, standard definition. / Lamm, Donald; Persad, Raj; Brausi, Maurizio; Buckley, Roger; Witjes, J. Alfred; Palou, Joan; Böhle, Andreas; Kamat, Ashish M.; Colombel, Marc; Soloway, Mark.

In: Journal of Urology, Vol. 191, No. 1, 01.01.2014, p. 20-27.

Research output: Contribution to journalArticle

Lamm, D, Persad, R, Brausi, M, Buckley, R, Witjes, JA, Palou, J, Böhle, A, Kamat, AM, Colombel, M & Soloway, M 2014, 'Defining progression in nonmuscle invasive bladder cancer: It is time for a new, standard definition', Journal of Urology, vol. 191, no. 1, pp. 20-27. https://doi.org/10.1016/j.juro.2013.07.102
Lamm, Donald ; Persad, Raj ; Brausi, Maurizio ; Buckley, Roger ; Witjes, J. Alfred ; Palou, Joan ; Böhle, Andreas ; Kamat, Ashish M. ; Colombel, Marc ; Soloway, Mark. / Defining progression in nonmuscle invasive bladder cancer : It is time for a new, standard definition. In: Journal of Urology. 2014 ; Vol. 191, No. 1. pp. 20-27.
@article{82a12592dc0b4f5f9662a838d33dd235,
title = "Defining progression in nonmuscle invasive bladder cancer: It is time for a new, standard definition",
abstract = "Purpose: Despite being one of the most important clinical outcomes in nonmuscle invasive bladder cancer, there is currently no standard definition of disease progression. Major clinical trials and meta-analyses have used varying definitions or have failed to define this end point altogether. A standard definition of nonmuscle invasive bladder cancer progression as determined by reproducible and reliable procedures is needed. We examine current definitions of nonmuscle invasive bladder cancer progression, and propose a new definition that will be more clinically useful in determining patient prognosis and comparing treatment options. Materials and Methods: The IBCG (International Bladder Cancer Group) analyzed published clinical trials and meta-analyses that examined nonmuscle invasive bladder cancer progression as of December 2012. The limitations of the definitions of progression used in these trials were considered, as were additional parameters associated with the advancement of nonmuscle invasive bladder cancer. Results: The most commonly used definition of nonmuscle invasive bladder cancer progression is an increase in stage from nonmuscle invasive to muscle invasive disease. Although this definition is clinically important, it fails to include other important parameters of advancing disease such as progression to lamina propria invasion and increase in grade. Conclusions: The IBCG proposes the definition of nonmuscle invasive bladder cancer progression as an increase in T stage from CIS or Ta to T1 (lamina propria invasion), development of T2 or greater or lymph node (N+) disease or distant metastasis (M1), or an increase in grade from low to high. Investigators should consider the use of this new definition to help standardize protocols and improve the reporting of progression.",
keywords = "administration, BCG vaccine, disease progression, drug therapy, intravesical, urinary bladder neoplasms",
author = "Donald Lamm and Raj Persad and Maurizio Brausi and Roger Buckley and Witjes, {J. Alfred} and Joan Palou and Andreas B{\"o}hle and Kamat, {Ashish M.} and Marc Colombel and Mark Soloway",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.juro.2013.07.102",
language = "English",
volume = "191",
pages = "20--27",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Defining progression in nonmuscle invasive bladder cancer

T2 - It is time for a new, standard definition

AU - Lamm, Donald

AU - Persad, Raj

AU - Brausi, Maurizio

AU - Buckley, Roger

AU - Witjes, J. Alfred

AU - Palou, Joan

AU - Böhle, Andreas

AU - Kamat, Ashish M.

AU - Colombel, Marc

AU - Soloway, Mark

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose: Despite being one of the most important clinical outcomes in nonmuscle invasive bladder cancer, there is currently no standard definition of disease progression. Major clinical trials and meta-analyses have used varying definitions or have failed to define this end point altogether. A standard definition of nonmuscle invasive bladder cancer progression as determined by reproducible and reliable procedures is needed. We examine current definitions of nonmuscle invasive bladder cancer progression, and propose a new definition that will be more clinically useful in determining patient prognosis and comparing treatment options. Materials and Methods: The IBCG (International Bladder Cancer Group) analyzed published clinical trials and meta-analyses that examined nonmuscle invasive bladder cancer progression as of December 2012. The limitations of the definitions of progression used in these trials were considered, as were additional parameters associated with the advancement of nonmuscle invasive bladder cancer. Results: The most commonly used definition of nonmuscle invasive bladder cancer progression is an increase in stage from nonmuscle invasive to muscle invasive disease. Although this definition is clinically important, it fails to include other important parameters of advancing disease such as progression to lamina propria invasion and increase in grade. Conclusions: The IBCG proposes the definition of nonmuscle invasive bladder cancer progression as an increase in T stage from CIS or Ta to T1 (lamina propria invasion), development of T2 or greater or lymph node (N+) disease or distant metastasis (M1), or an increase in grade from low to high. Investigators should consider the use of this new definition to help standardize protocols and improve the reporting of progression.

AB - Purpose: Despite being one of the most important clinical outcomes in nonmuscle invasive bladder cancer, there is currently no standard definition of disease progression. Major clinical trials and meta-analyses have used varying definitions or have failed to define this end point altogether. A standard definition of nonmuscle invasive bladder cancer progression as determined by reproducible and reliable procedures is needed. We examine current definitions of nonmuscle invasive bladder cancer progression, and propose a new definition that will be more clinically useful in determining patient prognosis and comparing treatment options. Materials and Methods: The IBCG (International Bladder Cancer Group) analyzed published clinical trials and meta-analyses that examined nonmuscle invasive bladder cancer progression as of December 2012. The limitations of the definitions of progression used in these trials were considered, as were additional parameters associated with the advancement of nonmuscle invasive bladder cancer. Results: The most commonly used definition of nonmuscle invasive bladder cancer progression is an increase in stage from nonmuscle invasive to muscle invasive disease. Although this definition is clinically important, it fails to include other important parameters of advancing disease such as progression to lamina propria invasion and increase in grade. Conclusions: The IBCG proposes the definition of nonmuscle invasive bladder cancer progression as an increase in T stage from CIS or Ta to T1 (lamina propria invasion), development of T2 or greater or lymph node (N+) disease or distant metastasis (M1), or an increase in grade from low to high. Investigators should consider the use of this new definition to help standardize protocols and improve the reporting of progression.

KW - administration

KW - BCG vaccine

KW - disease progression

KW - drug therapy

KW - intravesical

KW - urinary bladder neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84890120075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890120075&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2013.07.102

DO - 10.1016/j.juro.2013.07.102

M3 - Article

C2 - 23973937

AN - SCOPUS:84890120075

VL - 191

SP - 20

EP - 27

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1

ER -